Micro-Cap Investing

Business

Nvidia's Earnings Loom: Does Timing Your Buy Before Feb. 25 Matter? Historical Data Suggests Patience

As Nvidia prepares to report its fiscal Q4 earnings on February 25th, investors are weighing whether to buy ahead of the event. While the AI chip leader's long-term story remains compelling, a look at its recent post-earnings stock performance reveals a pattern that favors a measured approach over trying to time the market.

Feb 2, 2026

Business

Navigating Economic Uncertainty: Nine Practical Strategies to Fortify Your Savings in 2026

Amid persistent inflation and shifting trade policies, building a robust financial safety net is more crucial than ever. Experts outline actionable steps to grow your savings, from debt management to smart account allocation.

Feb 2, 2026

Business

Penny Stocks in Focus: Siebert Financial Tops List as Investors Seek High-Growth Opportunities

Amid a mixed market backdrop, penny stocks are drawing renewed attention for their growth potential. We analyze three standout picks, led by financial services firm Siebert Financial, highlighting their financial health and strategic moves in a volatile landscape.

Feb 2, 2026

Business

Visa and Mastercard Post Strong Quarterly Gains, Fueling Debate Over Long-Term Value

The payments giants Visa and Mastercard reported robust revenue and earnings growth for their latest quarters, though their premium valuations continue to spark investor debate on which offers the superior long-term opportunity.

Feb 2, 2026

Business

Gallagher Posts Strong Q4 Earnings, but Truist Cuts Price Target Amid Sector Valuation Concerns

Insurance brokerage giant Arthur J. Gallagher reported robust fourth-quarter profit growth, driven by resilient demand. However, Truist Securities has lowered its price target on the stock, citing valuation pressures across the property & casualty brokerage sector.

Feb 2, 2026

Business

Medicare's Obesity Drug Coverage Set to Fuel Lilly's Weight-Loss Pill Launch, CEO Says

Eli Lilly's CEO sees Medicare's new policy covering obesity treatments as a pivotal moment, poised to unlock access for millions of beneficiaries to its incoming oral drug, orforglipron, and intensify the market battle with Novo Nordisk.

Feb 2, 2026

Business

Disney Posts Strong Q1 Earnings Amid CEO Succession Speculation

The Walt Disney Company exceeded Wall Street expectations in its fiscal first quarter, delivering robust results across its entertainment, experiences, and streaming divisions as longtime CEO Bob Iger prepares to hand over the reins later this year.

Feb 2, 2026

Business

Insider Confidence: Three High-Growth Stocks Where Leadership Has Skin in the Game

Amid a resilient but mixed market, companies with significant insider ownership are drawing investor attention. We examine three firms—spanning crypto, consumer staples, and finance—where management's substantial equity stakes align with ambitious earnings growth forecasts of up to 124%.

Feb 2, 2026

World

A Nation Preparing for the Inevitable: Zimbabwe's Funeral Insurance Boom Overshadows Healthcare Crisis

In Zimbabwe, where formal employment is scarce and medical costs are prohibitive, a stark financial choice is being made: affordable funeral policies are vastly outpacing health insurance, reflecting a cultural prioritization of dignified burials over accessible healthcare.

Feb 2, 2026

Business

Disney's Q1 Earnings: Theme Parks and Streaming Drive Revenue Growth, But Linear TV Weakness Weighs on Profits

The Walt Disney Company reported a 5% rise in fiscal first-quarter revenue to $26 billion, fueled by its theme parks and streaming services. However, operating profit fell 9% as challenges in its traditional TV business and rising costs offset gains.

Feb 2, 2026

Business

Analysts See Hidden Value in CuriosityStream: Stock Could Be Undervalued by Over 20%

A new financial analysis suggests shares of the documentary-focused streaming service CuriosityStream may be trading significantly below their estimated intrinsic value, presenting a potential opportunity for investors.

Feb 2, 2026

Business

Vidhance's Cash Runway: A Closer Look at the Video Tech Firm's Financial Position

While Vidhance (FRA:8W50) continues to operate at a loss, its current cash reserves and manageable burn rate suggest the company has time to execute its growth strategy. However, a recent dip in revenue adds a note of caution for investors.

Feb 2, 2026

Business

Rhythm Pharmaceuticals: The Under-the-Radar Biotech Outpacing Tech Giants

While investors chase AI and big tech, a niche biotech firm focused on rare genetic obesity disorders has quietly delivered staggering returns, with Wall Street seeing further 40% upside. Rhythm Pharmaceuticals' targeted approach and upcoming catalysts have analysts bullish, despite its relative anonymity.

Feb 2, 2026

Business

NovaGold's Valuation Puzzle: High Hopes for Donlin Gold Clash with Recent Market Volatility

Shares of NovaGold Resources (TSX:NG) have tumbled roughly 20% in the past week, reigniting debate over the gold developer's premium valuation. While long-term shareholders have seen stellar returns, the recent pullback forces a fresh look at the risks and rewards priced into its ambitious Donlin project.

Feb 2, 2026

Business

Apollo Bets Big on AI Infrastructure and Logistics, Signaling Strategic Pivot

Apollo Global Management is deploying billions into AI data center infrastructure and European logistics real estate, underscoring a strategic shift towards hard assets tied to technological transformation and supply chain resilience.

Feb 2, 2026

Business

Beyond the Penny Stock Stigma: Three European Small-Caps with Solid Footing

Amidst a cautiously optimistic economic backdrop in Europe, we examine three publicly traded companies with market capitalizations exceeding €30 million that combine the growth potential of small-caps with notable financial resilience.

Feb 2, 2026

Business

InflaRx's Cash Runway Narrows: Can the Biotech Steer Through Financial Headwinds?

With a cash reserve that could last just over a year at its current burn rate, InflaRx faces a critical period to prove its clinical pipeline's value. While management has reined in spending, the company's financial strategy is now under the microscope.

Feb 2, 2026

Business

Hilton's Five-Year Surge: How a Hospitality Giant Delivered a 169% Return to Investors

While market volatility tests many sectors, Hilton Worldwide Holdings has charted a remarkable course. Shareholders have seen total returns near 169% over five years, a performance fueled by a return to profitability and strategic execution that outpaced broader market trends.

Feb 2, 2026

Business

Beyond the Bottom Line: Two Profitable Stocks Building Momentum, One Facing Headwinds

Profitability alone doesn't guarantee a stock's success. We examine three companies with strong margins, highlighting two that are leveraging their financial health for growth and one where challenges may cloud the future.

Feb 2, 2026

Business

EyePoint's Stock Soars 195% in Three Years Despite Persistent Losses, Sparking Investor Debate

While EyePoint Pharmaceuticals (EYPT) shares have retreated 23% this month, long-term shareholders are still sitting on massive gains. The biotech's 195% three-year surge, despite ongoing losses, highlights a classic market puzzle: balancing current financials with future potential.

Feb 2, 2026